DNTH
Dianthus Therapeutics, Inc. /DE/
NASDAQ · Healthcare · Biotechnology · US
$79.33
+3.32%Price chart
Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26
Key dataOct 26, 2026
Open$77.48
From 52W high−31.59%
Volume500731.00
Market cap$4.44B
P/E (TTM)—
P/S (TTM)2330.5x
Div yield—
Key dataOct 26, 2026
Open
$77.48
From 52W high
−31.59%
Volume
500731.00
Market cap
$4.44B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−120.3x
P/E (TTM)
—
RSI (14)
33.7
MomentumView details →
1D Return
+3.32%
YTD Return
+88.28%
SummaryUpdated Jun 1, 2026
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is a clinical-stage biotechnology company founded in 2015 and headquartered in New York, New York. The company went public in June 2018 and focuses on developing novel monoclonal antibody treatments for patients suffering from severe autoimmune and inflammatory diseases. Dianthus is currently advancing its lead drug candidate, DNTH103, through Phase 1 clinical trials for multiple neurological conditions including generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Similar companies
Latest newsMore news →
Dianthus Therapeutics is advancing DNTH312, a first-in-class bifunctional fusion protein, aiming to be Phase 1 ready by year-end 2027.83d agoDianthus Therapeutics is advancing DNTH212 for Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis, with Phase 1 healthy volunteer data anticipated by year-end 2026.83d ago